These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37584397)

  • 1. Approach to the Patient: Youth-Onset Type 2 Diabetes.
    Hitt TA; Hannon TS; Magge SN
    J Clin Endocrinol Metab; 2023 Dec; 109(1):245-255. PubMed ID: 37584397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
    Nadeau DA
    Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of type 2 diabetes mellitus in youth : which therapies?
    Miller JL; Silverstein JH
    Treat Endocrinol; 2006; 5(4):201-10. PubMed ID: 16878999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes.
    Bacha F; Klinepeter Bartz S
    Pediatr Diabetes; 2016 Dec; 17(8):545-558. PubMed ID: 26592507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance in type 2 diabetic youth.
    Mizokami-Stout K; Cree-Green M; Nadeau KJ
    Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):255-62. PubMed ID: 22732484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reevaluating First-line Therapies in Youth-Onset Type 2 Diabetes.
    Chung ST; Davis F; Patel T; Mabundo L; Estrada DE
    J Clin Endocrinol Metab; 2024 Jan; 109(2):e870-e872. PubMed ID: 37624230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic outcomes of surgery in youth with type 2 diabetes.
    Shah AS; Nadeau KJ; Helmrath MA; Inge TH; Xanthakos SA; Kelsey MM
    Semin Pediatr Surg; 2020 Feb; 29(1):150893. PubMed ID: 32238292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The present and future treatment of pediatric type 2 diabetes.
    Van Name MA; Guandalini C; Steffen A; Patel A; Tamborlane W
    Expert Rev Endocrinol Metab; 2018 Jul; 13(4):207-212. PubMed ID: 30063424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world treatment escalation from metformin monotherapy in youth-onset Type 2 diabetes mellitus: A retrospective cohort study.
    Vajravelu ME; Hitt TA; Amaral S; Levitt Katz LE; Lee JM; Kelly A
    Pediatr Diabetes; 2021 Sep; 22(6):861-871. PubMed ID: 33978986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
    Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
    Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin therapy in type 2 diabetes.
    Mudaliar S; Edelman SV
    Endocrinol Metab Clin North Am; 2001 Dec; 30(4):935-82. PubMed ID: 11727406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success.
    Aguilar RB
    Clin Ther; 2011 Apr; 33(4):408-24. PubMed ID: 21635988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes.
    Cravalho CKL; Meyers AG; Mabundo LS; Courville A; Yang S; Cai H; Dai Y; Walter M; Walter PJ; Sharma S; Chacko S; Cogen F; Magge SN; Haymond MW; Chung ST
    Diabetologia; 2020 Oct; 63(10):2194-2204. PubMed ID: 32728891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.